ReviewChinese medical journal2021

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.

Ying Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.